ZA201307169B - Neuroprotective peptides - Google Patents

Neuroprotective peptides

Info

Publication number
ZA201307169B
ZA201307169B ZA2013/07169A ZA201307169A ZA201307169B ZA 201307169 B ZA201307169 B ZA 201307169B ZA 2013/07169 A ZA2013/07169 A ZA 2013/07169A ZA 201307169 A ZA201307169 A ZA 201307169A ZA 201307169 B ZA201307169 B ZA 201307169B
Authority
ZA
South Africa
Prior art keywords
neuroprotective peptides
neuroprotective
peptides
Prior art date
Application number
ZA2013/07169A
Other languages
English (en)
Inventor
Elhanan Pinner
Nava Zisapel
Original Assignee
Neurim Pharmaceuticals (1991) Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurim Pharmaceuticals (1991) Ltd filed Critical Neurim Pharmaceuticals (1991) Ltd
Publication of ZA201307169B publication Critical patent/ZA201307169B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585CD44
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ZA2013/07169A 2011-03-24 2013-09-18 Neuroprotective peptides ZA201307169B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161466966P 2011-03-24 2011-03-24
PCT/IL2012/050104 WO2012127475A1 (en) 2011-03-24 2012-03-22 Neuroprotective peptides

Publications (1)

Publication Number Publication Date
ZA201307169B true ZA201307169B (en) 2014-05-28

Family

ID=45999925

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/07169A ZA201307169B (en) 2011-03-24 2013-09-18 Neuroprotective peptides

Country Status (13)

Country Link
US (1) US20140045764A1 (cg-RX-API-DMAC7.html)
EP (1) EP2688582B1 (cg-RX-API-DMAC7.html)
JP (1) JP5960793B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140036164A (cg-RX-API-DMAC7.html)
CN (1) CN103648517B (cg-RX-API-DMAC7.html)
AU (1) AU2012232642B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013024323A2 (cg-RX-API-DMAC7.html)
CA (1) CA2830792A1 (cg-RX-API-DMAC7.html)
EA (1) EA201391387A1 (cg-RX-API-DMAC7.html)
MX (1) MX2013010910A (cg-RX-API-DMAC7.html)
SG (1) SG193418A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012127475A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307169B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201220899D0 (en) * 2012-11-21 2013-01-02 Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh CD44v6-derived pegylated peptides
EP3409130B1 (en) * 2016-01-27 2020-11-25 Industry-Academic Cooperation Foundation Gyeongsang National University Composition for preventing, alleviating or treating neurological disorders, containing, as active ingredient, novel peptide activating adiponectin receptors
US10660934B2 (en) 2016-03-31 2020-05-26 Senju Pharmaceutical Co., Ltd. Neuroprotective peptide
JP7061561B2 (ja) * 2016-03-31 2022-04-28 千寿製薬株式会社 神経保護ペプチド
JP7695772B2 (ja) 2017-11-14 2025-06-19 千寿製薬株式会社 Pacapの安定化ペプチド
JP7260930B2 (ja) 2018-11-08 2023-04-19 ニオバスク ティアラ インコーポレイテッド 経カテーテル僧帽弁人工補綴物の心室展開
ES2991433T3 (es) 2019-05-14 2024-12-03 Senju Pharma Co Péptido de PACAP estabilizado
CN114173874B (zh) 2019-05-14 2025-07-25 千寿制药株式会社 含pacap肽或pacap的稳定化肽的神经营养性角膜炎的预防或治疗用组合物
CN112569351B (zh) * 2020-12-16 2021-10-15 南通大学 Cd44抗体在制备治疗帕金森疾病的药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
CA2165461A1 (en) * 1993-06-18 1995-01-05 Sirpa Jalkanen Compositions and diagnostic methods using monoclonal antibodies against cd44v6
EP0806965A4 (en) * 1994-01-18 2000-06-07 Harvard College EXPRESSION OF CD44 IN SMOOTH MUSCLE CELLS
DE19653607A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Int Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen
WO1999037317A1 (en) * 1998-01-24 1999-07-29 Bristol-Myers Squibb Company Artificial proteoglycans
DE602004027255D1 (de) * 2004-10-14 2010-07-01 Karlsruher Inst Technologie Peptidische Verbindungen und deren Ableitungen für die Behandllung von menschlichen Krankheiten durch Hemmung der Signalübertragung über Wachstumfaktoren
NZ582390A (en) * 2007-07-10 2012-05-25 Neurim Pharma 1991 Cd44 splice variants in neurodegenerative diseases
EP2266593A1 (en) * 2009-06-24 2010-12-29 Karlsruher Institut für Technologie Use of CD44v6 in the treatment of ophthalmic diseases

Also Published As

Publication number Publication date
SG193418A1 (en) 2013-10-30
EP2688582A1 (en) 2014-01-29
JP2014510101A (ja) 2014-04-24
MX2013010910A (es) 2014-03-27
JP5960793B2 (ja) 2016-08-02
CN103648517A (zh) 2014-03-19
CA2830792A1 (en) 2012-09-27
AU2012232642B2 (en) 2016-12-08
US20140045764A1 (en) 2014-02-13
EA201391387A1 (ru) 2014-01-30
EP2688582B1 (en) 2017-02-15
AU2012232642A1 (en) 2013-10-17
CN103648517B (zh) 2016-04-20
WO2012127475A1 (en) 2012-09-27
BR112013024323A2 (pt) 2017-06-13
KR20140036164A (ko) 2014-03-25

Similar Documents

Publication Publication Date Title
SG10201601840RA (en) P53 activating peptides
IL231604B (en) Therapeutic peptides
ZA201309174B (en) Polypeptides
IL233280B (en) Cell-penetrating peptides
EP2857033A4 (en) PEPTIDE WITH SKIN PERMEATION
GB201012651D0 (en) Peptides
ZA201307169B (en) Neuroprotective peptides
GB201111183D0 (en) Peptide
EP2753641A4 (en) NEUROPROTECTIVE CELL PENETRATING PEPTIDES
GB201115910D0 (en) Peptides
ZA201503127B (en) Peptides
GB201200555D0 (en) Peptide
GB201204868D0 (en) Peptides
GB201223114D0 (en) Novel peptide
HUE036243T2 (hu) PSF1-származék peptid
IL228354A0 (en) Neuroprotective peptides
GB201115014D0 (en) Peptides
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides
GB201105653D0 (en) Anti-microbial peptides
GB201221414D0 (en) Trans-locating peptide
GB201200624D0 (en) Peptide
GB201200623D0 (en) Peptide